- Home
- HRMY vs GTX Comparison
HRMY vs GTX Comparison
Compare HRMY & GTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRMY
- GTX
- Stock Information
- Founded
- HRMY 2017
- GTX 2018
- Country
- HRMY United States
- GTX Switzerland
- Employees
- HRMY N/A
- GTX N/A
- Industry
- HRMY Biotechnology: Pharmaceutical Preparations
- GTX Auto Parts:O.E.M.
- Sector
- HRMY Health Care
- GTX Consumer Discretionary
- Exchange
- HRMY Nasdaq
- GTX Nasdaq
- Market Cap
- HRMY 1.8B
- GTX 2.0B
- IPO Year
- HRMY 2020
- GTX N/A
- Fundamental
- Price
- HRMY $34.00
- GTX $11.33
- Analyst Decision
- HRMY Strong Buy
- GTX Strong Buy
- Analyst Count
- HRMY 9
- GTX 1
- Target Price
- HRMY $54.44
- GTX $14.00
- AVG Volume (30 Days)
- HRMY 642.5K
- GTX 3.1M
- Earning Date
- HRMY 08-05-2025
- GTX 07-24-2025
- Dividend Yield
- HRMY N/A
- GTX 2.13%
- EPS Growth
- HRMY 13.13
- GTX N/A
- EPS
- HRMY 2.62
- GTX 1.28
- Revenue
- HRMY $744,852,000.00
- GTX $3,438,000,000.00
- Revenue This Year
- HRMY $20.10
- GTX $1.06
- Revenue Next Year
- HRMY $18.01
- GTX $6.41
- P/E Ratio
- HRMY $13.10
- GTX $8.79
- Revenue Growth
- HRMY 20.62
- GTX N/A
- 52 Week Low
- HRMY $26.47
- GTX $7.02
- 52 Week High
- HRMY $41.61
- GTX $12.09
- Technical
- Relative Strength Index (RSI)
- HRMY 58.91
- GTX 63.54
- Support Level
- HRMY $31.70
- GTX $10.71
- Resistance Level
- HRMY $35.08
- GTX $11.57
- Average True Range (ATR)
- HRMY 0.95
- GTX 0.33
- MACD
- HRMY 0.27
- GTX 0.12
- Stochastic Oscillator
- HRMY 71.80
- GTX 88.25
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About GTX Garrett Motion Inc.
Garrett Motion Inc designs, manufactures and sells engineered turbocharger and electric-boosting technologies for light and commercial vehicle original equipment manufacturers (OEMs). The company is a technology leader with expertise in delivering products across gasoline, diesel, natural gas and electrified powertrains. The company also sells its technologies in the aftermarket through its distribution network. The company derives maximum of its revenue from Gas and geographically from Europe.